ORAL CONTROLLED RELEASE DRUG DELIVERY SYSTEM: AN OVERVIEW by Modi Kushal et al.
Modi Kushal et al. Int. Res. J. Pharm. 2013, 4 (3) 
Page 70 
  INTERNATIONAL RESEARCH JOURNAL OF PHARMACY 
www.irjponline.com  ISSN 2230 – 8407 
  Review Article 
 
ORAL CONTROLLED RELEASE DRUG DELIVERY SYSTEM: AN OVERVIEW 
Modi Kushal
1*, Modi Monali
2, Mishra Durgavati
2, Panchal Mittal
2, Sorathiya Umesh
3, Shelat Pragna
1 
1Department of Pharmaceutics and Pharmaceutical Technology, K. B. Institute of Pharmaceutical Education and Research,  
Kadi Sarva Vishwavidyalaya, Gandhinagar, Gujarat, India 
2Department of Pharmaceutical Technology, L. J. Institute of Pharmacy, Ahmadabad, Gujarat, India 
3Department of Pharmaceutics, Indukaka Ipcowala College of Pharmacy, Vithal Udyog nagar, Gujarat, India 
Email: kushal.modi@gmail.com 
 
Article Received on: 10/01/13 Revised on: 01/02/13 Approved for publication: 11/03/13 
 
DOI: 10.7897/2230-8407.04312 
IRJP is an official publication of Moksha Publishing House. Website:  www.mokshaph.com.  
© All rights reserved.  
 
ABSTRACT 
Oral drug delivery is the most preferred and convenient option as the oral route provides maximum active surface area among all drug delivery system for 
administration of various drugs. The attractiveness of these dosage forms is due to awareness to toxicity and ineffectiveness of drugs when administered by 
oral conventional method in the form of tablets and capsules. Usually conventional dosage form produces wide range of fluctuation in drug concentration in 
the bloodstream and tissues with consequent undesirable toxicity and poor efficiency. The maintenance of concentration of drug in plasma within therapeutic 
index is very critical for effective treatment. These factors as well as factors such as repetitive dosing and unpredictable absorption lead to the concept of oral 
controlled release drug delivery systems. Controlled release drug delivery system works on many different mechanisms to control the release rate of drugs. 
Various mechanisms like osmotic pressure, matrix system, reservoir system, altered density system etc. have been utilized as formulation approaches. The 
present article contains brief review on various formulation approaches for controlled release drug delivery system. 
Keywords: Controlled release drug delivery system, matrix type system, reservoir system. 
 
INTRODUCTION 
Over  the  Past  30  years,  as  the  expense  and  complications 
involved in marketing new drug entities have increased, with 
concomitant  recognition  of  the  therapeutic  advantages  of 
controlled drug delivery,  greater attention is  being paid on 
development of oral controlled release drug delivery systems. 
The goal in designing controlled release drug delivery system 
is to reduce the frequency of the dosing, reducing the dose 
and providing uniform drug delivery. So, controlled release 
dosage form is a dosage form that releases one or more drugs 
continuously in predetermined pattern for a fixed period of 
time, either systemically or locally to specified target organ 
1-
3. Controlled release dosage forms provide better control of 
plasma drug levels, less dosage frequency, less side effect, 
increased  efficacy  and  constant  delivery.  The  modified 
release oral delivery system classification is shown in figure 
1 
3,4 . 
 
Controlled Release Drug Delivery System  
Controlled release system  means  any drug delivery  system 
that maintains adequate and desired release of drug over an 
extended  period  of  time.  Hydrophilic  polymer  matrix  is 
widely used  for  formulating  an  controlled dosage  form 
2-4. 
The role of ideal drug delivery system is to provide proper 
amount of drug at regular time interval and at right site of 
action to maintain therapeutic range of drug in blood plasma. 
The IR drug delivery system lacks some features like dose 
maintenance, controlled release rate and site targeting.  The 
oral  controlled drug delivery has some  potential advantage 
like controlled release rate and dose maintenance in plasma. 
The CR formulations have some swelling polymer or waxes 
or both which controls the release rate. The use of reservoir 
system is also well known for controlling release rate. Figure 
2  shows  the  relation  between  plasma  concentration  verses 
time. 
 
 
Advantages  of  controlled  release  drug  delivery  system 
over the conventional dosage form 
4 
·  Reduced dosing frequency.  
·  Dose reduction. 
·  Improved patient compliance. 
·  Constant level of drug concentration in blood plasma. 
·  Reduced toxicity due to overdose.  
·  Reduces the fluctuation of peak valley concentration. 
·  Night time dosing can be avoided. 
 
Limitation of Oral Conventional Dosage Form
2, 3 
1. Poor patient compliance, increased chances of missing the 
dose  of  a  drug  with  short  half  life  for  which  frequent 
administration is necessary. 
2. The unavoidable  fluctuations  of drug concentration  may 
lead  to  under  medication  or  over  medication  in  narrow 
therapeutic index drug. 
3. A typical peak-valley plasma concentration time profile is 
obtained  which  makes  attainment  of  steady-state  condition 
impossible. 
 
Factors  affecting  the  Formulation  of  Oral  controlled 
release Drug delivery system  
 
Physicochemical factors  
 
Aqueous Solubility 
Most of the drugs are weak acids or weak bases Drugs with 
low  water  solubility  will  be  difficult  to  incorporate  into 
sustained  release  mechanism 
2,  5.  For  a  drug  with  high 
solubility and rapid dissolution rate, it is often quite difficult 
to retard its dissolution rate. A drug of high water solubility 
can  dissolve  in  water  or  gastrointestinal  fluid  readily  and 
tends  to  release  its  dosage  form  in  a  burst  and  thus  is 
absorbed  quickly  leading  to  a  sharp  increase  in  the  blood 
drug concentration compared to less soluble drug. It is often 
difficult  to  incorporate  a  highly  water  soluble  drug  in  the Modi Kushal et al. Int. Res. J. Pharm. 2013, 4 (3) 
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dosage form and retard the drug release especially when the 
dose is high. The pH dependent solubility particularly in the 
physiological  pH  range  would  be  another  problem  for 
controlled release formulation because of the variation in the 
pH throughout the gastrointestinal tract and variation in the 
dissolution rate. The biopharmaceutical classification system 
(BCS) allows estimation of likely contribution of three major 
factors  solubility,  dissolution  and  intestinal  permeability 
which affect the oral absorption.  
Class III (High solubility- Low permeability) and Class IV 
(Low solubility- Low permeability) drugs are poor candidates 
for controlled release dosage form compound with solubility 
<  0.1  mg/ml  face  significant  solubilisation  obstacles  and 
often  compounds  with  solubility  10  mg/ml  present 
difficulties to solubilisation dosing  formulation.  In  general, 
highly soluble drugs are undesirable for formulation in to a 
controlled release product. 
 
Partition coefficient (P (o/w)) 
Partition coefficient is defined as the fraction of drug in an oil 
phase to that of an adjacent aqueous phase. Drugs that passes 
though biological membrane, if partition co-efficient of drug 
influences  shows  very  much  bioavailability  because 
lipophilic  nature  of  biological  membrane.  Drugs  that  have 
lower partition coefficient are not suitable for oral CR drug 
delivery  system  and  drugs  that  have  higher  partition  co-
efficient  are  also  not  suitable  for  oral  CR  drug  delivery 
system  because  they  will  not  partition  out  of  the  lipid 
membrane once it gets in the membrane 
5.  
 
Drug pKa and ionization at physiological pH 
Drugs existing largely in ionized form are poor candidates for 
oral controlled release drug delivery system. Absorption of 
the unionized drugs are well whereas permeation of ionized 
drug is negligible because the absorption rate of ionized drug 
is 3-4 times less than that of the unionized drug. The pKa 
range  for  acidic  drug  whose  ionization  is  pH  sensitive  is 
around 3.0-7.5 and pKa range for basic drug whose ionization 
is  pH  sensitive  is  around  7.0-11.0  are  ideal  for  optimum 
positive absorption. Drug shall be unionized at the site to an 
extent 0.1-5.0% 
2.  
 
Drug stability 
Drugs  undergo  both  acid/base  hydrolysis  and  enzymatic 
degradation when administered oral route. If the drug in the 
solid state the degradation will occur in reduced rate, for the 
drugs that are unstable in stomach that prolong delivery to the 
entire  GI  tract  are  beneficial.  If  drug  is  administered  in 
extended  release  dosage  form  that  are  unstable  in  small 
intestine  may  demonstrate  decreased  bioavailability.  This 
occurs  due  to  the  fact  that  a  greater  quantity  of  drug  is 
delivered in small intestine and is being subjected to  more 
degradation 
8-10. 
 
Molecular size and diffusivity 
Diffusivity depends on size and shape of the cavities of the 
membrane 
7.  The  diffusion  co-efficient  of  intermediate 
molecular weight drug is 100-400 Daltons; through flexible 
polymer  range  is  10
-6-10
-9  cm
2/sec.  For  drugs  having 
molecular weight > 500 Daltons, the diffusion coefficient in 
many polymers are very less i.e. less than 10
-12 cm
2/sec. The 
examples of drugs which are difficult to control release rate 
of medicament from dosage form are proteins and peptides. 
 
 
Biological Factor 
The absorption behaviour of a drug can affect its suitability 
as  an  extended  release  product.  The  aim  of  formulating 
controlled release product is to place a control on the delivery 
system 
2. It is essential that the rate of release is much slower 
than the rate of absorption. If we assume the transit time of 
dosage forms in the absorptive areas of GI tract is about 8-12 
hours,  the  maximum  half-life  for  absorption  should  be 
approximately  3-4  hours.  Otherwise  the  dosage  form  will 
pass  out  of  absorptive  regions  before  drug  release  is 
complete. Therefore, the compounds with lower absorption 
rate constants are poor candidates. Some possible reasons for 
low  extent  of  absorption  are  poor  water  solubility,  small 
partition co-efficient, acid hydrolysis and metabolism or its 
site of absorption. The distribution of drugs in tissues can be 
important  factor  in  the  overall  drug  elimination  kinetics. 
Since it not only lowers the concentration of circulating drug 
but it also can be rate limiting in its equilibrium with blood 
and extra  vascular tissue, consequently  apparent  volume of 
distribution  assumes  different  values  depending  on  time 
course of drug disposition. Drugs with high apparent volume 
of distribution, which influence the rate of elimination of the 
drug are poor candidate for oral CR drug delivery system. For 
design  of  sustained  release  products,  formulation  scientist 
must have information on disposition of the drug. 
A drug which extensively metabolizes is not suitable for CR 
drug  delivery  system.  A  drug  capable  of  inducing 
metabolism, inhibiting metabolism, metabolized at the site of 
absorption  or  first-pass  effect  is  poor  candidate  for  CR 
delivery, as it could be difficult to maintain constant blood 
level. Drugs that are metabolized before absorption, either in 
lumen  or  the  tissues  of  the  intestine,  can  show  decreased 
bioavailability  from  the  controlled  releasing  systems.  Most 
intestinal  walls  are  saturated  with  enzymes.  As  drug  is 
released  at  a  slow  rate  to  these  regions,  lesser  drug  is 
available in the enzyme system. Hence, the systems should be 
devised so that the drug remains in that environment to allow 
more complete conversion of the drug to its metabolite. 
 
Half-life 
The half-life of a drug is an index of its residence time in the 
body. If the drug has short half life (less than 2 hours) the 
dosage form may contain a prohibitively large quantity of the 
drug. On the other hand, drug with elimination half-life of 8 
hours or more are sufficiently controlled in the body, when 
administered  in  conventional  dosage  from  and  controlled 
release  drug  delivery  system  is  generally  not  necessary  in 
such  cases.  Ideally,  the  drug  should  have  half-life  of  3-4 
hours for formulation of drug delivery system
 2-5. 
 
Therapeutic index 
Drugs  with  low  therapeutic  index  are  unsuitable  for 
incorporation in controlled release formulations. If the system 
fails in the body, dose dumping may occur, which leads to 
toxicity
 5. 
 
Size of dose 
If the dose of a drug in the conventional dosage form is high, 
then it is less suitable candidates for CRDDS. This is because 
the  size  of  a  unit  dose  controlled  release  oral  formulation 
would become too big to administer without difficulty 
6. 
 
Absorption window 
Certain  drugs  when  administered  orally  are  absorbed  only 
from  a  specific  part  of  gastrointestinal  tract.  This  part  is Modi Kushal et al. Int. Res. J. Pharm. 2013, 4 (3) 
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referred to as the ‘absorption window’. These candidates are 
also not suitable for CRDDS
 7. 
 
Plasma concentration response relationship 
Generally, plasma drug concentration is more responsible for 
pharmacological  activity  rather  than  dose.  But  the  drug 
having  pharmacological  activity  independent  of  plasma 
concentrations, are poor candidate for oral CR drug delivery 
system 
6. 
 
Concentration dependency on transfer of drug 
Transfer of drug from one compartment to other, if follows 
zero order kinetic process then such drugs are poor candidate 
for  oral  CR  delivery  system.  It  should  be  of  first  order 
kinetics
7.  The  figure  3  represents  various  formulation 
strategies for oral controlled release drug delivery system. 
 
Diffusion Sustained System 
Diffusion  process  shows  the  movement  of  drug  molecules 
from  a  region  of  a  higher  concentration  to  one  of  lower 
concentration. 
 
Diffusion reservoir system 
In this system, a water insoluble polymeric material covers a 
core  of  drug.  Drug  will  partition  into  the  membrane  and 
exchange  with  the  fluid  surrounding  the  particle  or  tablet. 
Additional  drug  will  enter  the  polymer,  diffuse  to  the 
periphery  and  exchange  with  the  surrounding  media.  The 
drug  release  takes  place  by  diffusion  mechanism.  The 
diffusion type reservoir system is shown in figure 4. 
Advantages 
·  Zero order delivery is possible. 
·  Release rates can be modified with polymer type and 
concentration. 
Disadvantages 
·  Difficult to deliver high molecular weight compound. 
·  Generally increased cost per dosage unit. 
·  Potential toxicity if dose dumping occurs. 
 
Diffusion matrix system 
The matrix system is defined as a well-mixed composite of 
one  or  more  drugs  with  gelling  agent  i.e.  hydrophilic 
polymers. Matrix systems are widely used for sustaining the 
release  rate.  It  is  the  release  system  which  prolongs  and 
controls the release of the drug that is dissolved or dispersed 
7, 18. A solid drug is dispersed in an insoluble matrix and the 
rate  of  release  of  drug  is  dependent  on  the  rate  of  drug 
diffusion  and  not  on  the  rate  of  solid  dissolution.  The 
diffusion type matrix system is shown in figure 5. 
Advantages 
·  Easier to produce than reservoir or encapsulated devices. 
·  Versatile, effective and low cost.  
·  Possible to formulate high molecular weight compounds.  
·  Increased  the  stability  by  protecting  the  drug  from 
hydrolysis or other derivative changes in gastrointestinal 
tract.   
Disadvantages 
·  The ghost matrix must be removed after the drug has been 
released.  
·  The release rates are affected by various factors such as, 
food and the rate transit through the gut.  
·  Cannot provide pure zero order release. 
 
 
Types of diffusion matrix system  
The  matrix  system  can  be  divided  into  two  categories 
depending  on  the  types  of  retarding  agents  or  polymeric 
materials 
11. 
·  Hydrophobic matrix system 
·  Hydrophilic matrix system 
·  Fat-wax matrix system 
Hydrophobic matrix system 
This  is  the  only  system  where  the  use  of  polymer  is  not 
essential  to  provide  controlled  drug  release,  although 
insoluble polymers can been used. As the term suggests, the 
primary rate controlling components of hydrophobic matrix 
are  water  insoluble  in  nature.  These  ingredients  include 
waxes glycerides fatty acids, and polymeric materials such as 
ethyl cellulose, methyl cellulose and acrylate copolymer. To 
modulate  drug  release,  it  may  be  necessary  to  incorporate 
soluble  ingredients  such  as  lactose  into  formulation.  The 
presence of insoluble ingredient in the formulations helps to 
maintain  the  physical  dimension  of  hydrophobic  matrix 
during drug release. Diffusion of active ingredient from the 
system  is  the  release  mechanism  and  the  corresponding 
release characteristic can be described by Higuchi equation 
also known as square root of time release kinetic 
11. 
 
Hydrophilic matrix system  
The primary rate limiting ingredients of hydrophilic matrix 
are polymers that would swell when in contact with aqueous 
solution and form a gel layer on the surface of the system 
18-
20.  When  the  release  medium  is  thermodynamically 
compatible  with  a  polymer,  the  solvent  penetrates  into  the 
free  spaces  between  macromolecular  chains.  The  polymer 
may  undergo  a  relaxation  process  due  to  the  stress  of  the 
penetrated solvent, so that the polymer chains become more 
flexible and the matrix swells. This allows the encapsulated 
drug to diffuse more rapidly out of the matrix. On the other 
hand, it would take more time for drug to diffuse out of the 
matrix since matrix swelling lengthens the diffusion path. It 
has been widely known that swelling and diffusion are not 
the only factors that determine the rate of drug release. For 
dissolvable  polymer  matrix,  polymer  dissolution  is  another 
important  mechanism  that  can  modulate  the  drug  delivery 
rate.  While  either  swelling  or  dissolution  can  be  the 
predominant factor for a specific type of polymers, in most 
cases  drug  release  kinetics  is  a  result  of  a  combination  of 
these two mechanisms. The presence of water decreases the 
glass transition temperature (Tg) (for HPMC from 184°C to 
below 37°C), giving rise to transformation of glassy polymer 
to rubbery phase (gel layer).  The enhanced  motility  of the 
polymeric  chain  favors  the  transport  of  dissolved  drug. 
Polymer  relaxation  phenomena  determine  the  swelling  or 
volume increase of the matrix. The main polymers used in 
hydrophilic  matrices  are  hydroxy  propyl  methyl  cellulose 
(HPMC) and Hydroxy propyl cellulose (HPC), Xanthan gum, 
Carbopol and Alginates.  
 
Fat-Wax matrix tablet  
The drug can  be incorporated into fat wax  granulations by 
spray  congealing  in  air,  blend  congealing  in  an  aqueous 
media with or without the aid of surfactant and spray-drying 
techniques 
12, 13. In the bulk congealing method, a suspension 
of drug and melted fat-wax is allowed to solidify and is then 
comminuted for sustained release granulations. The mixture 
of active ingredients, waxy materials and fillers also can be 
converted into granules by compacting with roller compactor, 
heating in a suitable mixture such as fluidized-bed and steam Modi Kushal et al. Int. Res. J. Pharm. 2013, 4 (3) 
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jacketed  blender  or  granulating  with  a  solution  of  waxy 
material or other binders. The drug embedded into a melt of 
fats and waxes is released by leaching and/ or hydrolysis as 
well as dissolution of fats under the influence of enzymes and 
pH  change  in  the  gastrointestinal  tract.  The  addition  of 
surfactants  to  the  formulation  can  also  influence  both  the 
drug release rate and the proportion of total drug that can be 
incorporated into a matrix. 
 
Dissolution Controlled Systems  
A drug with a slow dissolution rate is inherently sustained 
and  for  those  drugs  with  high  water  solubility,  one  can 
decrease  dissolution  through  appropriate  salt  or  derivative 
formation
13, 14. These systems are most commonly employed 
in the production of enteric coated dosage forms. To protect 
the  stomach  from  the  effects  of  drugs  such  as  Aspirin,  a 
coating that dissolves in natural or  alkaline  media is used. 
This inhibits release of drug  from the dosage  form until it 
reaches the higher pH of the intestine. In most cases, enteric 
coated dosage  forms are not truly sustaining in nature, but 
serve as a useful function in directing release of the drug to a 
special  site.  The  same  approach  can  be  employed  for 
compounds that are degraded by the harsh conditions found 
in the gastric region. 
 
Soluble reservoir system 
In this system drug is coated with a given thickness coating, 
which is slowly dissolved in the contents of gastrointestinal 
tract by alternating layers  of drug with the rate controlling 
coats  as  shown  in  figure  6.  A  pulsed  delivery  can  be 
achieved, if the outer layer is quickly releasing bolus dose of 
the drug, initial levels of the drug in the body can be quickly 
established with pulsed intervals. This is not a true sustained 
release  system;  the  biological  effects  can  be  similar.  An 
alternative method is to administer the drug as group of beads 
that have coating of different thickness. 
Since the beads have different coating thickness, their release 
occurs  in  a  progressive  manner.  Those  with  the  thinnest 
layers will provide the initial dose. The maintenance dose of 
drug can be achieved by applying thicker coating. This is the 
principle of the spansule capsule. Cellulose nitrate phthalate 
was  synthesized  and  used  as  an  enteric  coating  agent  for 
acetyl salicylic acid tablets. 
 
Soluble matrix system  
It  can  be  either  a  drug  impregnated  sphere  or  a  drug 
impregnated tablet, which will be subjected to slow erosion 
14, 15. The more common type of dissolution sustained dosage 
form is shown in figure 7.  
 
Dissolution- sustained pulsed delivery systems  
Amongst controlled release formulations hydrophilic matrix 
technology  is  the  most  widely  used  due  to  its  following 
advantages 
16, 17. 
·  Provide desired release profile for a wide therapeutic drug 
category, drug and solubility. 
·  Simple and cost effective manufacturing and robust. 
·  Patient acceptance. 
·  Ease  of  drug  modulation  through  level,  choice  of 
polymeric systems and function coating. 
A  hydrophilic  matrix  tablet  consists  of  mixture  of  drug, 
polymer  and  excipients  (filler/diluents  as  well  as  other 
excipients)  prepared  by  hydrophilic  polymer  in  the  matrix.  
Formulators  often  choose  from  a  range  of  hydrophilic 
polymer  as  stand  alone  or  in  combination  with  different 
polymers for release rate control. 
 
Ion Exchange Resins Controlled Release
  
Ion  exchange  resins  are  cross-linked  water-insoluble 
polymers carrying ionisable functional groups 
27. The resins 
have  been  used  in  various  pharmaceutical  applications, 
primarily for taste masking and controlled release systems. In 
tablet formulations, ion exchange resins have  been used as 
disintegrant,  because  of  their  swelling  ability.  It  forms 
irreversible  complex  with  ionisable  drugs  upon  prolonged 
exposure  of  the  drug  to  the  resin.  A  resin  bound  drug  is 
removed  when  appropriate  ions  are  in  contact  with  ion-
exchanged groups. The area and length of diffusion pathway 
and the amount of cross-linked polymer in the resin moiety 
governs  the  rate  of  drug  release.  Sriwongjanya  et  al.  has 
found the effect of ion exchange resin with drug containing 
opposite  charge  in  matrix  system.  After  this  investigation 
they concluded that the release of drug containing opposite 
charge  retarded  by  the  addition  of  ion  exchange  resin  to 
HPMC-matrices due to formation of complex between drug 
and resin.  
 
Methods using Osmotic Pressure
  
In  this  method,  the  release  controlling  factor  that  must  be 
optimized is the osmotic pressure gradient between inside the 
compartment and the external environment 
28, 29. The simplest 
and  most  predictable  way  to  achieve  a  constant  osmotic 
pressure is to maintain a saturated solution of osmotic agent 
in  the  compartment.  This  technology  provides  zero  order 
release used for hydrophilic drugs. Drug may be osmotically 
active  or  combine  with  osmotically  active  salt  eg.  NaCl. 
Osmotic pressure is the hydrostatic pressure produced by a 
solution in a space divided by a semi permeable membrane 
due to difference in concentration of solutes. Osmosis is the 
diffusion of fluid through a semi permeable membrane from a 
solution with a low solute concentration to a solution with a 
higher  solute  concentration  until  there  is  an  equal 
concentration of fluid on both sides of the membrane. A semi 
permeable  membrane  is  placed  around  a  tablet,  particle  or 
drug  solution  that  allows  transport  of  water  into  the  tablet 
with  eventual  pumping  of  drug  solution  out  of  the  tablet 
through  a  small  delivery  aperture  in  tablet  coating.  The 
osmotic systems are classified in major two types, i.e. type-A 
and  type-B.  In  type-A  system,  the  core  contains  both,  the 
drug  and  electrolytes.  The  electrolytes  provide  osmotic 
pressure  and  maintain  the  rate  of  drug  release.  In  type-B 
system,  the  drug  solution  is  present  in  a  semi  permeable 
membrane surrounded by the electrolytes. Both the systems 
are shown in figure 8 and 9 respectively. 
The OCODDS can be conveniently classified in to following 
types:
 22-24 
 
Single chamber osmotic pump 
·  Elementary osmotic pump (EOP) 
 
Multi chamber osmotic pump 
·  Push pull osmotic pump. 
·  Osmotic pump with non expanding second chamber. 
 
Specific types 
·  Controlled porosity osmotic pump. 
·  Monolithic osmotic systems. 
·  Osmotic bursting osmotic pump. Modi Kushal et al. Int. Res. J. Pharm. 2013, 4 (3) 
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·  OROS – CT 
·  Multi particulate delayed release systems (MPDRS) 
·  Liquid Oral Osmotic System (L-OROS) 
 
pH Independent Formulations
  
Most drugs are either weak acids or weak bases. The release 
from  controlled  release  formulations  is  pH  dependent. 
However; buffers such as salts of  amino acids, citric acid, 
phthalic acid phosphoric acid or tartaric acid can be added to 
the  formulation  to  help  to  maintain  a  constant  pH  thereby 
rendering  pH  independent  drug  release 
25,  26.  A  buffered 
formulation is prepared by mixing a basic or acidic drug with 
one  or  more  buffering  agent,  granulating  with  appropriate 
pharmaceutical  excipients  and  coating  with  gastrointestinal 
fluid permeable film forming polymer. When gastrointestinal 
fluid permeates through the membrane, the buffering agents 
adjust  the  fluid  inside  to  suitable  constant  pH  thereby 
rendering a constant rate of drug release.  
 
Table 1: Marketed drug products with their mechanism based classification 
 
SN  Technology  Brand name  Drug  Manufacturer 
1.  Diffusion controlled release  Welbutrin XL  Bupropion  GlaxoSmithKline 
2.  Matrix system tablet  Ambien CR  Zolpidem Tartarate  Sanofi-Aventis 
3.  Method using ion Exchange  Tussionex Pennkinetic 
ER suspension 
Hydrocodone Polistirex and 
Chlorpheneramine Polistirex 
UCB Inc. 
4.  Methods using 
Osmotic pressure 
Elementary Osmotic Pump  Efidac 24®  Chlorpheniramine Maleate  Novartis 
Push-Pull Osmotic Systems  Glucotrol XL®  Glipizide  Pfizer Inc. 
5.  pH independent formulation  Inderal® LA  Propranolol HCl  Wyeth Inc. 
6.  Altered density formulation  Modapar  Levodopa and Benserazide  Roche Products, USA 
 
 
 
Figure 1: Classification of modified release drug delivery system 
 
 
 
Figure 2: Ideal plasma concentration curves for immediate release, Zero order release, sustained release drug delivery system 
 
 
 
Figure 3: formulation strategy for oral controlled release drug delivery system 
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Figure 4: Schematic representation of diffusion type reservoir system 
 
 
 
Figure 5: Schematic representation of diffusion type matrix system 
 
 
 
Figure 6: Schematic representation of dissolution of reservoir system 
 
 
 
Figure 7:  Schematic representation of dissolution matrix system 
 
 
 
Figure 8: Type-A osmotic system 
 
 
Figure 9: Type-B osmotic system 
 
Altered Density Formulations  
Several  approaches  have  been  developed  to  prolong  the 
residence time of drug delivery system in the gastrointestinal 
tract 
21, 22. The delivery system remains in the vicinity of the 
absorption site until most, if not all of its drug contents is 
released. In high density approach, the density of the pellets 
must  exceed  that  of  normal  stomach  content  and  should 
therefore be at least 1-4g/cm
3. In low density approach, the 
globular  shells  which  have  an  apparent  density  lower  than 
that  of  gastric  fluid  can  be  used  as  a  carrier  of  drug  for 
sustained  release  purpose.  There  are  several  reasons  for 
attractiveness  of  these  dosage  forms:  provides  increased 
bioavailability of drug product. This system is generally used 
when, the single dose for the duration of treatment whether 
for days or weeks as with infection, diabetes or hypertension 
is required.  
 
CONCLUSION 
The controlled release drug delivery system aims to release 
the drug at the desired rate over extended period of time to 
maintain the therapeutic level in blood. Nowadays, the oral 
route of  administration for controlled release drug delivery 
system has received more attention due to its more flexibility, 
reduced dosing frequency and better patient compliance. The 
design  of  oral  controlled  release  drug  delivery  system 
depends on  various  factors like, physic-chemical properties 
of  drug,  type  of  delivery  system,  disease  being  treated, 
patient  condition,  treatment  duration,  presence  of  food, 
gastrointestinal motility and co-administration of other drugs. 
From  the  above  discussion,  we  can  concluded  that  the 
controlled  release  drug  delivery  system  is  very  helpful  in 
increasing the efficiency  of the dose as well as the patient 
compliance. Moreover; the reasonable cost of oral controlled 
release  drug  delivery  system  has  lead  ease  of  market 
penetration as replacement of oral conventional drug delivery 
system. 
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